The Preservation Arc
The Preservation Arc: Losing Fat Without Losing Your Foundation
The scale moves, but the lifter’s question stays the same: what am I keeping? Body-composition research helps separate fat loss, lean mass, and the claims around growth-hormone peptides.
Key takeaways
- 1.Weight loss can include fat and lean mass; lean mass is not identical to muscle.
- 2.A hormone change does not by itself demonstrate improved strength or muscle retention.
- 3.Tesamorelin’s specific medical indication should not be stretched into a general bodybuilding claim.
Protect what the first season built
The shirt is fitting differently. The waist measurement is changing. His old photos show progress he missed in the mirror.
Then a hard session makes him nervous. The bar feels heavier than last week.
He has spent years becoming strong. He does not want a smaller number on the scale to erase that foundation.
This is where peptide discussions often shift from appetite to muscle preservation—and where precise language becomes essential.
Read the body-composition panel carefully
The SURMOUNT-1 body-composition substudy found that tirzepatide reduced body weight, fat mass, and lean mass compared with placebo. [1]
That finding is more useful than either “it burns only fat” or “it destroys muscle.” Both slogans flatten a more complicated result.
Lean mass includes tissues and water beyond skeletal muscle. A scan result does not directly describe how strong someone is, how they move, or whether a short-term change reflects muscle tissue alone.
For a lifter, the picture includes several measurements: weight trend, waist, training performance, physical function, and nutritional intake. No single one tells the whole story.
Why the hormone shortcut sounds convincing
Growth hormone and IGF-1 have biological roles in growth and metabolism. That makes compounds affecting those pathways interesting research subjects.
It also makes them easy to oversell.
A human study of CJC-1295 demonstrated changes in growth-hormone secretion. [2] A change in secretion is an endocrine finding. It is not automatically evidence that a recreational lifter will preserve muscle during a cut.
The precise molecule matters too. Research on a long-acting, albumin-binding CJC-1295 formulation cannot simply be assigned to every product sold under a similar name.
Ipamorelin often enters the same conversation. The missing step is still the same: where is the controlled evidence for the exact physique outcome being promised? Naming two compounds together does not answer that question.
Tesamorelin has a defined clinical context
The FDA prescribing information for EGRIFTA WR describes tesamorelin for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight-loss management. [3]
That is an important example of a real drug with a specific purpose. A result in that population is not a general prescription for belly fat in gym users.
Visceral fat, scale weight, and visible abdominal definition are related topics, but they are not interchangeable endpoints.
Keep the training chapter active
The character closes the tab promising a perfect preservation stack and opens his training log.
The next useful questions are ordinary: is he recovering, eating adequately, and keeping a sustainable training stimulus? Does a persistent decline in function need evaluation rather than another internet solution?
Peptide research belongs in this chapter. So does the discipline of refusing to turn a plausible mechanism into a guaranteed result.
The foundation is worth protecting carefully.
Science check
Analysis // 09What we know
- Incretin-associated weight loss can include lean-mass reduction. Specific growth-hormone-axis studies can demonstrate hormonal effects.
What remains uncertain
- Whether untested peptide combinations preserve muscle or improve performance during a lifter’s cut.
Power scale · strength of evidence
These labels describe support for a specific claim, not product ratings.
- Tirzepatide body-composition findingsHuman clinical evidence
Human trial substudy.
- CJC-1295 hormonal effectsLimited human evidence
Human physiology evidence.
- Tesamorelin for its labeled medical useHuman clinical evidence
Indication-specific clinical and regulatory evidence.
- Extrapolated muscle-preservation stack claimsNot established
Not established by the studies cited here.
Training log // 09
- 01 · Performance and function
- Follow performance and function alongside weight. Bring sustained weakness or difficulty meeting nutritional needs to the clinician managing care.
Publisher disclosure: Recomp Report is published by The Peptide Gallery, LLC, the team behind TPG Bioscience, an affiliated research-products business. You can learn more about the affiliated business at TPG Bioscience. This relationship does not establish the clinical benefits or safety of any research product discussed here.
Limitations
Educational discussion, not advice to manipulate growth hormone or IGF-1. No dosing or stacking recommendations. The recurring character is fictional and is not a patient testimonial or evidence that a compound caused his transformation.
Sources
- 1.Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight, 2025.
- 2.Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting growth hormone-releasing hormone analog, 2006.
- 3.FDA: EGRIFTA WR prescribing information, 2025.
Your next arc starts with better information.
Body composition, metabolic health, training and emerging research—without the hype. Plus occasional updates from our affiliated research business, TPG Bioscience.
Educational information only. This article does not provide medical advice, diagnosis, dosing, or treatment recommendations.
Related articles
The Training Arc: How to Rebuild Yourself When You've Always Been the Big Guy
You've been big, you've gotten strong, and now you want to change your body. Here's how to approach fat loss and recomposition without pretending you're starting from zero.
Recomp Report Editorial Team · 26 September 2026
The Cut Arc: How to Lose Fat Without Losing the Muscle You Built
The cut is where you reveal what you built—but cut too hard and you reveal a smaller, weaker you. What research says about rate of loss, protein, training and diet breaks.
Recomp Report Editorial Team · 29 September 2026
The Control Arc: Semaglutide, Tirzepatide, and the New Appetite Story
Hunger was never just a test of character. Incretin-based medicines changed the conversation by targeting biological signals—and newer research is asking what comes next.
Recomp Report Editorial Team · 12 October 2026